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ABSTR ACT: Sternal wound infections represent one of the most frequent complications after cardiac surgery and are associated with high postoperative 
mortality. Several preventive methods have been introduced, and recently, gentamicin-impregnated collagen sponges (GICSs) have shown a promising 
effect in reducing the incidence of this type of complications. Gentamicin is an aminoglycoside antibiotic that has been widely used to treat infections caused 
by multiresistant bacteria; despite its effectiveness, its systemic use carries a risk of toxicity. GICSs appear to overcome this side effect, topically delivering 
high antibiotic concentrations to the wound and thus reducing the toxic-related events. Although several retrospective analyses and randomized controlled 
trials have studied the use of GICSs in cardiac surgery, conclusions regarding their efficacy in preventing sternal wound infection are inconsistent. We have 
reviewed the current literature focusing on high-risk patients.
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Introduction
Sternal wound infections (SWIs) represent one of the most 
challenging postoperative complications following cardiac 
surgery, associated with increased hospital stay, mortality, 
and costs.1 It is widely acknowledged that several factors 
(eg, smoking, obesity, insulin-dependent diabetes, emer-
gent surgery, prolonged operative time, reoperation, bilateral 
internal mammary artery (BIMA) harvesting, transfusions, 
and prolonged ventilation/intensive care unit [ICU] stay) 
pre dispose to a higher risk of both superficial and deep 
SWIs; many of these conditions are observed with increas-
ing frequency in the modern cardiac surgery scenario.2–4 
Historically, the cornerstones of prevention of SWIs have 
been preoperative skin asepsis and administration of pro-
phylactic antimicrobial drugs and several surgical maneuvers 
intended to maintain sterility and achieve a stable sternal 
fixation.5–7 During the past few years, local administration 
of gentamicin through a surgically inserted collagen sponge 
has been gaining popularity in different surgical fields, and it 
has been increasingly used in cardiac surgery.8 The reported 
incidence of SWIs varies between 0.5% and 6% through-
out the literature, although it is considerably higher among 
high-risk individuals, ranging between 12% and 20%.6 SWIs 
can be classified as super ficial SWIs (SSWIs) or deep SWIs 
(DSWIs), according to the extension of the infective process 
from the skin and subcutaneous layer to the bone and medi-
astinum. The Centers for Disease Control and Prevention and 
the National Institute of Clinical Excellence have developed 
guidelines for the diagnosis and management of surgical site 
infections.9,10 However, currently, the assessment and treat-
ment of SWIs seem to be quite heterogeneous among differ-
ent centers and even among different surgeons from the same 
center. It is clear that DSWIs strongly impact on postopera-
tive morbidity and mortality and that SSWIs are a common 
cause of prolonged hospital stay. In 2008, Mauermann et al 
reviewed data regarding 11 series of postoperative SWIs, 
reporting an overall mortality of 13% (ranging between 6% 
and 30%). They also concluded that it is difficult to precisely 
assess the impact of SWIs on hospital costs due to the vari-
ability in protocols among different centers.1 Since SWIs 
significantly prolong ICU stay and hospitalization, they are 
widely known to be a major cause of increased health-care 
costs in cardiac surgery.1 Both DSWIs and SSWIs are usually 
caused by gram-positive skin bacteria such as Coagulase-
negative staphylococci (CoNS) and Staphylococcus aureus; in a 
minority of cases, they can be caused by gram-negative rods 
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such as Escherichia coli and Pseudomonas aeruginosa and fungi 
such as Candida albicans.11–13 As shown in Table 1, gram-
positive bacteria are isolated in 60%–80% of postoperative 
SWIs, gram-negative rods in 20%–40% of cases, and fungi in 
about 5% (polymicrobial isolations are frequent and occur in 
10%–40% of cases).1,14,15
The emergence of multiresistant bacterial strains has led 
to a challenging situation: beta-lactam antibiotics have become 
ineffective against most CoNS and S. aureus clusters, and 
the routine use of vancomycin as a prophylactic agent is not 
advisable in order to avoid further antibiotic resistances.13,16 
Furthermore, CoNS have the intrinsic ability to adhere to 
foreign bodies (eg, sternal wires) and produce a biofilm, thus 
increasing their resistance to antibiotics and the probability of 
a chronic infection.17,18
Advantages of Gentamicin Local Delivery
Local administration of antibiotics such as gentamicin, tobra-
mycin, tetracycline, minocycline, teicoplanin, and sulbactam–
cefoperazone has been performed in several surgical fields.8 
Gentamicin has gradually become the most used molecule for 
this purpose due to a combination of characteristics such as 
broad spectrum, low cost, and favorable pharmacokinetics and 
pharmacodynamics when administered topically.8,19
Gentamicin is an aminoglycoside antibiotic that has been 
widely used to treat infections caused by multiresistant bacte-
ria (Fig. 1). Although its spectrum is mainly directed toward 
gram-negative species, gentamicin is also effective against 
several gram-positive strains.19 Furthermore, gentamicin 
also shows a synergy with beta-lactam antibiotics, especially 
against gram-positive species such as S. aureus and CoNS.16 
Nevertheless, the principal factor limiting its systemic use 
is represented by its intrinsic toxicity; when administered 
intravenously or intramuscularly, gentamicin accumulates into 
renal cortex and into endolymph and perilymph of the inner 
ear, causing kidney injury and hearing loss.20 These drawbacks 
can be partially eluded by administering gentamicin locally, 
reducing the systemic toxicity. Kidney and inner ear accumu-
lations seem to appear when gentamicin serum concentration 
exceeds 10–12 mg/L, although a precise cutoff has not been 
established.8,21 Interestingly, it has been observed that, after 
local administration in the sternal region, the drug serum 
concentration does not exceed 1  mg/L, while mediastinal 
fluid concentration remains above 300 mg/L for 36 hours.21 
Moreover, gentamicin exhibits a concentration-dependent 
effect, especially against gram-negative rods: this means that 
a high concentration of the drug circumscribed to the surgical 
site can lead to a bactericidal effect not only toward sensi-
tive bacteria but also toward poorly sensitive or even resis-
tant ones;20 an acute peak concentration in the surgical site, 
combined with a low serum level of the drug, is protective 
against the selection of resistant bacteria; in fact, prolonged 
high serum concentrations promote the so-called adaptive 
resistance to gentamicin.20
Pharmacokinetics of GICS
Surgical implants impregnated with gentamicin started to be 
used in the 1970s, primarily in orthopedic surgery, aiming to 
treat or prevent prosthetic infections. The first devices had the 
disadvantage that they were not made of reabsorbable materi-
als; hence, they had to be surgically removed once the infec-
tion had been treated.22
As a consequence, biodegradable polymers such as poly-
lactic acid, polyglycolic-polylactic acid, poly(ortho esters), and 
polyhydroxybutyrate-co-hydroxyvalerate were developed to 
carry antibiotic drugs to the surgical site.23,24
Finally, since the 1980s, collagen implants began to be 
used in several surgical specialties for local antibiotic delivery, 
mainly due to collagen biocompatibility and pharmacokinetic 
versatility.23,24
Regarding pharmacokinetics, collagen is a unique poly-
mer because it has a complex, well-known three-dimensional 
structure with different hierarchical levels: primary, secondary, 
tertiary, and quaternary.25 The physiochemical characteristics 
Table 1. Microbiology of sWIs.
MICROORGANISM FREQUENCY
gram-positive Cocci 60–80%
Staphylococcus aureus 40–45%
Coagulase-negative staphylococcus 20–35%
gram-negative rods 20–40%
Enterobacter spp 10%
Pseudomonas spp 2–10%
Klebsiella spp 3–8%
Escherichia coli 5%
Proteus spp 2–3%
Fungi 5%
Polymicrobial 10–40%
Note: adapted from refs. 1,14,15.
Figure 1. Chemical structure of gentamicin.
Notes: atoms are represented as spheres with conventional color 
coding: white represents hydrogen, gray represents carbon, blue 
represents nitrogen, and red represents oxygen.
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of the final polymer can be modified by intervening on the 
molecular structure (eg, intra- and intermolecular cross-links) 
as well as linking collagen with other polymers to obtain dif-
ferent drug-releasing temporal curves. Hence, when collagen 
is used as a carrier for a drug, any structural modification can 
lead to different pharmacokinetic profiles.8,26,27
Collagen biocompatibility and absorbability represent 
essential characteristics with respect to infection prevention 
or treatment, because they allow to avoid a further surgical 
procedure (which could be as well complicated by infection) to 
remove the drug-carrying device.
Gentamicin-impregnated collagen sponges (GICSs) can 
be inserted in three different regions during sternal closure, 
depending on the desired primary site of action:
–	 behind the posterior surface of the sternum, between the 
bone and the sternal wires;
–	 between sternal halves; and
–	 on the anterior surface of the sternum, under the muscu-
lar fascia.
Every different position of the GICS corresponds to a 
slightly different spatial distribution of gentamicin, according 
to the closest sternal region.28,29 For instance, when a GICS 
was placed posteriorly to the sternum, its effect was more evi-
dent in preventing DSWI rather than SSWI.30
One or two GICSs per patient, corresponding to 130 
and 260 mg of gentamicin, respectively, were used in most of 
the reviewed studies, with various combinations of the above-
mentioned positions. There is some evidence that collagen 
sponges should not be soaked in saline solution prior to use.31,32 
Bennett-Guerrero et al conducted a multicenter random-
ized double-blind trial comparing high-risk cardiac surgical 
patients receiving a GICS with patients receiving a standard 
sternal closure. The authors found no advantages for the study 
group over the control group regarding the incidence of SWI 
up to 90 days after surgery. The GICS were soaked in saline as 
per the study protocol, and the authors have been criticized due 
to this maneuver.31 Gentamicin is a highly water-soluble mol-
ecule, and in vitro studies have showed that exposing a GICS 
to saline causes the loss of 6.7%, 40.5%, and 100% of the gen-
tamicin after 2 seconds, 1 minute, and 6 hours, respectively.32 
Manufacturers recommend not to soak the GICS prior to use.
GICS use in High-risk Cardiac Surgery Patients
Obesity represents one of the most important risk factors 
for the development of SWI in cardiac surgery,15 but there 
are contrasting data on the effect of the GICS on preventing 
this complication in this subgroup of patients. An important 
multicenter randomized controlled trial has involved 1502 
high-risk patients in 48 centers (Table 2).31 In this study, 
1006 patients (67% of the population) were diabetic and 1137 
patients (76%) were obese with a median body mass index 
(BMI) of 32.9 kg/m2. With a 90-day postoperative follow-up, 
the authors reported a comparable incidence of SWIs in the 
intention-to-treat analysis, with an incidence of DSWI of 8.4% 
in the GICS group vs 8.7% in the control group (P = 0.83). 
Similar results have been reported in the per-protocol analysis 
(8.4% vs 8.6%, P = 0.89). A further subanalysis of this study, 
targeting the very high-risk group and including patients who 
Table 2. Comparison of various studies that have investigated gICs use in high-risk cardiac surgery patients.
AUTHOR TYPE OF STUDY SUBGROUP OUTCOME GICS NO GICS P-VALUE
Bennett-guerrero 
et al31 Multicenter rCT, 1502 pts
all pts
any sWI (ITT) 8.4% 8.7% 0.83
any sWI (PP) 8.4% 8.6% 0.89
BMI  30 any sWI 8.1% 4.2% 0.07
Diabetes any sWI 4% 5.4% 0.52
BMI  30 + diabetes any sWI 11.1% 13.8% 0.30
Friberg et al16 Two-centers rCT, 2000 pts
all pts
any sWI 4.3% 9% 0.001
ssWI 1.9% 5.7% 0.001
DsWI 2.3% 3.3% 0.20
no reoperation or 
early death
ssWI 2.7% 6.7% 0.001
DsWI 2.1% 3.3% 0.088
Diabetes
ssWI 1.67% 7.47% 0.0086
DsWI 3.89% 9.77% 0.028
BMI  25
ssWI 2.16% 6.45% 0.001
DsWI 2.47% 4.45% 0.050
Birgand et al35 single center Cs, 552 pts BIMa + BMI  30 or 
ID diabetes
DsWI 12.6% 13.8% ns
Abbreviations: BIMa, bilateral internal mammary; Cs, cohort study; DsWI, deep sternal wound infection; BMI, body mass index; gICs, gentamicin-impregnated 
collagen sponge; ID, insulin-dependent; ITT, intention-to-treat; NS, not significant; PP, per-protocol; pts, patients; RCT, randomized controlled trial; SSWI, superficial 
sternal wound infection; sWI, sternal wound infection.
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were both obese and diabetic, showed no differences between 
the two groups (11.1% vs 13.8%, P = 0.30). The authors con-
cluded that the use of a GICS did not reduce the 90-day SWI 
rate.31 One of the most controversial points regarding this 
study was the fact that the GICS was wetted in saline before 
application: the consequence of this may have influenced the 
gentamicin release,32,33 and therefore the outcome of the study 
would have been affected.
Different results were reported by a previously published 
randomized controlled trial,16 where the impact of obesity was 
specifically subanalyzed. With a cutoff of BMI  25 kg/m2 
(1299 patients), the authors reported a significantly reduced 
incidence of SSWIs (2.16% vs 6.45%, P  0.001) and DSWIs 
(2.47% vs 4.45%, P = 0.05) in the GICS group. The analy-
sis of the whole population confirmed these results only for 
SSWIs, whereas there were no differences in terms of DSWIs 
(P = 0.2); these outcomes can be interpreted as a stronger effect 
of GICS in preventing DSWI in the obese group of patients.
Another subgroup at high risk of SWI includes patients 
who undergo BIMA harvesting during coronary artery 
bypass grafting (CABG), as this technique can impair sternal 
vascularization.34 A single-center study, published in 2012 by 
Birgand et al (Table 2), compared the incidence of DSWI requir-
ing surgery in high-risk patients defined as BIMA harvesting 
plus overweight (BMI  30 kg/m2) and/or insulin-dependent 
diabetes.35 The authors did not find any difference regarding 
the incidence of DSWI between patients receiving a GICS 
and those who did not receive it (12.6% vs 13.8%, respectively); 
interestingly, in that series, the probability of DSWI caused by 
a gentamicin-resistant bacterium was higher in the GICS group 
(21/27, 77.8%) compared with the other patients (23/56, 41.1%; 
P  0.01). Again, as in the above-mentioned study, GICS pre-
soaking in saline solution represented a weakness.
Once we consider the patients who undergo an early 
reoperation for bleeding (or other reasons) in the immediate 
postoperative course, the risk of a SWI is increased. In their 
prospective randomized trial, Friberg et al16 investigated the 
beneficial effect of GICS in 2000 patients undergoing cardiac 
surgery (Table 2); their results showed a reduced incidence of 
SWI at two months in the treatment group (4.3% vs 9%, RR 
0.47; 95% confidence interval [CI] 0.33–0.68, P  0.001). This 
result appears to be even more important if we consider that the 
treatment group had a higher number of early reoperations for 
bleeding (4% vs 2.3%, P = 0.03), thus suggesting that the use of a 
GICS is effective in reducing SWI even in the presence of early 
resternotomy. The authors repeated their analysis, excluding the 
patients reoperated for bleeding (or other reasons) and those who 
died within two months; in this subgroup, there was still a sig-
nificantly lower incidence of SSWIs (2.5% vs 6.7%, P = 0.001) 
and DSWIs (2.1 vs 3.3%, P = 0.088) in the GICS group.
In 2012, Creanor et al published a meta-analysis includ-
ing randomized controlled trials, which had previously inves-
tigated the use of GICS in cardiac surgery.36 One of the 
subanalyses of this study was conducted considering high-risk 
patients; a statistically significant difference between treatment 
and control group was found with regard to DSWIs (odds ratio 
[OR] 0.62, 95% CI 0.39–0.98), while no difference was found 
with regard to any SWI (OR 0.60, 95% CI 0.24–1.52).36
In a recent study published in 2014, Benedetto and Raja33 
identified the most important risk factors for DSWI after 
cardiac surgery. In their large analysis involving 8750 cardiac 
surgical patients, the authors identified several variables that 
can have an impact on the development of this complication: 
female gender, obesity, insulin-dependent diabetes, need for re-
exploration, isolated or combined CABG, and the use of bilat-
eral mammary artery.33 Using these variables, the authors were 
able to create a risk score to guide the use of GICS, demonstrat-
ing that an individual assessment of DSWI risk is realizable. 
Patients were classified as low, moderate, or high risk for 
DSWI, depending on their baseline score (Table 3 and Fig. 2). 
According to the authors’ findings, the use of GICS allowed 
to reclassify patients with moderate predicted risk of DSWI 
in the low-risk class. On the other hand, in high-risk patients, 
the observed DSWI incidence was lower than expected when 
a GICS was implanted, but the authors concluded that these 
patients should still be considered at higher risk.33 Till date, 
this score appears to be the only available guide in the decision-
making process for the use of GICS in cardiac surgery.
Conclusion
GICSs represent a promising option to prevent the occurrence 
of SWIs after heart surgery. Their main advantage is related 
to a high local concentration of gentamicin to the surgical site, 
combined with low serum levels of the drug, thus avoiding 
systemic side effects.
Most of the current knowledge on their use in cardiac 
surgery derives from underpowered studies, with different 
techniques of application. Hence, the real clinical beneficial 
effects in high-risk patients undergoing cardiac surgery have 
not been completely established, although there seems to be a 
tendency toward a reduced incidence of SWIs with their use. 
This is particularly evident when the device is not soaked in 
saline solution, as the results appear to be negatively affected 
by this maneuver.
Table 3. score to calculate DsWI predicted risk.
VARIABLE POINTS
Female gender 26
Insulin-dependent diabetes mellitus 20
CaBg (isolated or combined) 19
BIMa harvesting 15
need for re-exploration 51
BMI see Figure 2
Notes: Data from ref. 33. Overall score  136: low risk of DsWI. Overall 
score between 136 and 199: moderate risk of DsWI. Overall score  199: 
high risk of DsWI.
Abbreviations: CaBg, coronary artery bypass grafting; BMI, body mass index. 
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Currently, there are no guidelines on the use of GICS in 
cardiac surgery; the scoring system, proposed by Benedetto 
and Raja,33 seems to be the most reliable tool presently avail-
able for the indication of their use in high-risk patients.
However, further prospective randomized controlled 
trials, particularly in high-risk patients, are needed to better 
clarify the impact of GICS in preventing SWIs.
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Figure 2. Baseline score points according to BMI (Data from ref. 33).
Abbreviation: BMI, body mass index.
